Pharma

Your Article Summary

See Latest Articles

Lundbeck receives FDA Complete Response Letter on Serdolect for the treatment of schizophrenia
Lundbeck, 06/26/09

H. Lundbeck A/S announced today that the company has received a Complete Response Letter from the US Food and Drug Administration for Serdolect for the treatment of schizophrenia. The Agency's complete response included request for additional data to best understand the appropriate patient population for which Serdolect could be made available. Lundbeck is currently evaluating the feedback from FDA and will work with the Agency to resolve these outstanding questions and discuss appropriate next steps required to bring Serdolect safely to market.

Today in Regulatory Issues...keeping you current

Receive free subspecialty "5-minute updates" via email

Tricare contracts may be re-bid after losing plans protest
American Medical News , 11/25/09

GSK Regulatory Update: Avodart
GlaxoSmithKline, 11/24/09

Baytubes carbon nanotubes in marine coatings help reduce frictional resistance
BayNews International, 11/24/09

 See all of Regulatory Issues